Savara Past Earnings Performance

Past criteria checks 0/6

Savara has been growing earnings at an average annual rate of 1.9%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been declining at an average rate of 49% per year.

Key information

1.9%

Earnings growth rate

42.1%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate-49.0%
Return on equity-41.6%
Net Marginn/a
Last Earnings Update30 Sep 2024

Recent past performance updates

No updates

Recent updates

Savara: Trial Successful, But I'm Only Half Convinced

Sep 09

Savara: Today's Data 'Win' Rouses Market All Too Briefly

Jun 26

Savara: The Binary Bet On Phase 3 Data

Jun 07

Health Check: How Prudently Does Savara (NASDAQ:SVRA) Use Debt?

Dec 14
Health Check: How Prudently Does Savara (NASDAQ:SVRA) Use Debt?

Is Savara (NASDAQ:SVRA) Using Too Much Debt?

Feb 16
Is Savara (NASDAQ:SVRA) Using Too Much Debt?

Is Savara (NASDAQ:SVRA) Using Too Much Debt?

Oct 12
Is Savara (NASDAQ:SVRA) Using Too Much Debt?

Savara's rare lung disorder drug gets promising innovative medicine status in UK

Aug 26

Savara GAAP EPS of -$0.06 in-line

Aug 11

Does Savara (NASDAQ:SVRA) Have A Healthy Balance Sheet?

Jan 24
Does Savara (NASDAQ:SVRA) Have A Healthy Balance Sheet?

Is Savara (NASDAQ:SVRA) A Risky Investment?

Jul 05
Is Savara (NASDAQ:SVRA) A Risky Investment?

Savara: They Failed Once, But They Are Trying Again

Jun 07

The Independent Director of Savara Inc. (NASDAQ:SVRA), David Ramsay, Just Bought 565% More Shares

Mar 17
The Independent Director of Savara Inc. (NASDAQ:SVRA), David Ramsay, Just Bought 565% More Shares

Trade Alert: The Chairman & CEO Of Savara Inc. (NASDAQ:SVRA), Matthew Pauls, Has Just Spent US$50k Buying 4,415% More Shares

Feb 26
Trade Alert: The Chairman & CEO Of Savara Inc. (NASDAQ:SVRA), Matthew Pauls, Has Just Spent US$50k Buying 4,415% More Shares

Savara's IMPALA 2 Trial Seems Well-Tailored To Get Positive Phase 3 Data For Molgradex

Nov 24

Savara EPS misses by $0.01

Nov 05

Revenue & Expenses Breakdown

How Savara makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:SVRA Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-83220
30 Jun 240-752015
31 Mar 240-64180
31 Dec 230-55160
30 Sep 230-49140
30 Jun 230-431217
31 Mar 230-40120
31 Dec 220-38110
30 Sep 220-39110
30 Jun 220-39120
31 Mar 220-41120
31 Dec 210-43120
30 Sep 210-45120
30 Jun 210-46120
31 Mar 210-44120
31 Dec 200-50120
30 Sep 200-6812-30
30 Jun 200-6912-20
31 Mar 200-8113-10
31 Dec 190-78130
30 Sep 190-571340
30 Jun 190-571340
31 Mar 190-471139
31 Dec 180-621037
30 Sep 180-58834
30 Jun 180-52929
31 Mar 180-53724
31 Dec 170-31719
30 Sep 170-28716
30 Jun 170-25413
31 Mar 170-14410
31 Dec 160-1138
31 Dec 150-924
31 Dec 142-625

Quality Earnings: SVRA is currently unprofitable.

Growing Profit Margin: SVRA is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: SVRA is unprofitable, but has reduced losses over the past 5 years at a rate of 1.9% per year.

Accelerating Growth: Unable to compare SVRA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SVRA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: SVRA has a negative Return on Equity (-41.6%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies